Trinity Biotech Plc's Comment on Competition and Industry Peers
The Premier Hb9210 platform is positioned in the global HbA1c testing market and holds certification from the International Federation of Clinical Chemistry. The company also markets the Premier Resolution, a CE-cleared haemoglobinopathy analyzer available in the EU, which detects genetic disorders including sickle-cell disease and thalassemia. The Premier Resolution has been launched in Europe and the Middle East. The company faces regulatory risks such as potential litigation under healthcare reimbursement laws, consumer protection statutes, the federal Lanham Act, and FDA enforcement actions concerning promotional materials and sales activities.
August 14, 2025
In an important stride for maternal health, Trinity Biotech has secured regulatory approval from the New York State Department of Health (NYSDOH) to begin its PreClara Preeclampsia Testing Service. Set to launch in the third quarter of 2025, this innovative biomarker test aims to enhance the monitoring and management of hypertensive disorders during pregnancy, a condition that affects a significant number of expectant mothers worldwide.Hypertensive disorders, including preeclampsia, are among the leading causes of maternal and fetal morbidity and mortality. Preeclampsia is notoriously difficult to diagnose and can lead to severe health complications if not managed appropriately. The advent of the PreClara Ra...
October 7, 2024
Continuous Glucose Monitoring: Paving the Path for Enhanced Diabetes Management - A Closer Look at Trinity Biotech’s BreakthroughIn an era where innovative technologies are transforming healthcare, Trinity Biotech plc (Nasdaq: TRIB) has emerged as a promising player in the field of diabetes management. Recently, the company reported encouraging results from its first pre-pivotal clinical trial of its next-generation continuous glucose monitor (CGM), marking a significant milestone in its journey toward advancing diabetes care. The Breakthrough in Continuous Glucose MonitoringTrinity Biotech successfully completed its pre-pivotal trial in Europe, aimed at assessing the analytical performance of its newly e...
September 18, 2024
Trinity Biotech Sets Its Sights on Indian CGM Market in Partnership with Bayer Expanding Horizons in Diabetes ManagementIn a strategic move poised to redefine diabetes care, Dublin-based Trinity Biotech plc has announced a pioneering initiative in India, targeting the Continuous Glucose Monitoring (CGM) segment. This market entry marks a significant step in the company s global strategy, particularly in the expansive and dynamic Indian marketplace. Partnering with healthcare giant Bayer, Trinity Biotech aims to explore and understand the unique challenges and opportunities within the Indian diabetes management landscape. Continuous Glucose Monitoring: The New StandardCGMs have revolutionized the way diabete...
September 9, 2024
DUBLIN, Ireland Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company specializing in human diagnostics and diabetes management, announced significant progress in developing its continuous glucose monitor (CGM) technology. In a statement released on September 9, 2024, the company detailed its recent achievements, particularly in enhancing the performance of glucose biosensor technology.Earlier this year, Trinity Biotech received a European patent (EP3703565) for an innovative method that aims to boost the efficiency of indwelling sensors, including those used for glucose monitoring. This patent represents a critical step in advancing the company s capabilities in diabetes management, a sector that is i...
June 24, 2024
Trinity Biotech Initiates European Pre-Pivotal Trial for Optimization of CGM SensorTrinity Biotech plc, a leading biotechnology company focused on human diagnostics and diabetes management solutions, has recently taken significant steps towards the market launch of its next-generation continuous glucose monitoring (CGM) solution. With a focus on wearable biosensors, the company aims to further innovate and enhance the original CGM device that was acquired earlier this year. Trinity Biotech has now obtained regulatory approval to initiate its initial European pre-pivotal trial, which will serve as a key foundation for the larger pivotal trial required for product registration and subsequent market introducti...
May 16, 2024
DUBLIN, Ireland, May 16, 2024 - Trinity Biotech plc (Nasdaq: TRIB), a leading commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, announced today a monumental strategic collaboration with PulseAI, a cutting-edge medical artificial intelligence (AI) company. This partnership aims to elevate Trinity Biotech’s recently acquired continuous glucose monitor (CGM) biosensor technology to unprecedented levels of precision and efficiency. A Leap Toward Enhanced Diabetes Management SolutionsTrinity Biotech, renowned for its innovative solutions in the realm of human health diagnostics, has taken significant strides in diabetes management with its advancements i...
May 13, 2024
Trinity Biotech Experiences Increased Orders for TrinScreen HIV and Raises 2024 Sales GuidanceDUBLIN, Ireland, May 13, 2024 - Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company specializing in human diagnostics and diabetes management solutions, has recently disclosed a significant rise in orders for their product, TrinScreen HIV. This surge in orders has resulted in a total order value of approximately $6 million for the year 2024.Trinity Biotech s TrinScreen HIV is designed to provide accurate and reliable results for HIV diagnoses. The increased demand for this product highlights a growing need for effective HIV diagnostic solutions globally. Trinity Biotech s ability to secure substantial orders...
Sources:
Trinity Biotech Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Trinity Biotech Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
